Lakefront Biotherapeutics (LKFT) Capital Expenditures (QoQ) (2016 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (LKFT) Capital Expenditures (QoQ) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Lakefront Biotherapeutics | 1.88 Bn | 1.88 Bn | 3.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 92.29% |
| Dec 31, 2025 | 43.96% |
| Sep 30, 2025 | 29.16% |
| Jun 30, 2025 | 12.24% |
| Mar 31, 2025 | 7.47% |
| Dec 31, 2024 | -24.44% |
| Sep 30, 2024 | -30.18% |
| Jun 30, 2024 | 12.05% |
| Mar 31, 2024 | 79.80% |
| Mar 31, 2023 | 83.62% |
| Mar 31, 2022 | 83.39% |
| Jun 30, 2021 | -28.51% |
| Mar 31, 2021 | 79.81% |
| Jun 30, 2020 | -120.75% |
| Mar 31, 2020 | 87.23% |
| Dec 31, 2019 | -81.20% |
| Sep 30, 2019 | -315.35% |
| Jun 30, 2019 | -37.73% |
| Mar 31, 2019 | 79.85% |
| Dec 31, 2018 | -711.93% |